IP Library Granted Patent US 9,676,837
Granted Patent B2
US 9,676,837 · App. 14/236,403 · Granted Jun 13, 2017

Collagen 7 and related methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,676,837
App. No.
14/236,403
Granted
Jun 13, 2017
Kind
B2
Abstract

Disclosed are methods of making collagen 7, or functional fragments thereof, as well as collagen 7, and functional fragments thereof produced by such methods, nucleic acids encoding collagen 7, and functional fragments thereof, as well as vectors and host cells comprising such nucleic acids.

Claims (24)

1. A method of making human collagen 7, or a functional fragment of human collagen 7, comprising:

providing a cell, which comprises an exogenously introduced nucleic acid that encodes human collagen 7, or a functional fragment thereof, wherein said cell is recombinantly manipulated to express one or more polypeptides that increase expression of human collagen 7, or a functional fragment thereof, and wherein the one or more polypeptides comprises prolidase; and

culturing said cell under conditions sufficient for the production of human collagen 7, or the functional fragment of human collagen 7, and prolidase, thereby making human collagen 7, or the functional fragment thereof.

2. The method of claim 1 , wherein said cell is genetically manipulated to express a glycosyl transferase.

3. The method of claim 1 , wherein said cell comprises an exogenously introduced nucleic acid that encodes prolidase.

4. The method of claim 2 , wherein said cell comprises an exogenously introduced nucleic acid that encodes the glycosyl transferase.

5. The method of claim 1 , wherein said cell comprises an expression vector that comprises a sequence that encodes human collagen 7.

6. The method of claim 1 , further comprising recovering human collagen 7, or functional fragment thereof, from said cultured cell.

7. The method of claim 1 , wherein at least 30, 40, 50, 60, 70, 80, 90 or 95% of said human collagen 7, or functional fragment thereof, is incorporated into homotrimers.

8. The method of claim 1 , wherein at least 30, 40, 50, 60, 70, 80, 90 or 95% of said human collagen 7, or functional fragment thereof, is incorporated into hexamers.

9. The method of claim 1 , wherein the exogenously introduced nucleic acid that encodes human collagen 7, or the functional fragment thereof, is a high glycine codon-optimized nucleic acid sequence.

10. The method of claim 1 , wherein the cell is a fibroblast.

11. A cell comprising:

a first expression vector comprising a first nucleic acid sequence that encodes human collagen 7 or a functional fragment thereof,

a second expression vector comprising a second nucleic acid sequence that encodes one or more polypeptides that increase expression of human collagen 7, wherein said one or more polypeptides comprises prolidase, and

optionally a third expression vector comprising a third nucleic acid sequence that encodes glycosyl transferase.

12. The cell of claim 11 , which is in a cell culture.

13. A cell comprising:

a vector comprising a first nucleic acid sequence that encodes human collagen 7 or a functional fragment thereof, a second nucleic acid sequence that encodes prolidase, and optionally a third nucleic acid sequence that encodes glycosyl transferase.

14. A method of making a cell suitable for expressing human collagen 7, or a functional fragment thereof, comprising

recombinantly manipulating said cell to express recombinant human collagen 7, or the functional fragment thereof; and

recombinantly manipulating said cell to express one or more polypeptides that increase expression of human collagen 7, wherein the one or more polypeptides comprises recombinant prolidase;

thereby making a cell suitable for expressing recombinant human collagen 7, or the functional fragment thereof.

15. The method of claim 14 , further comprising recombinantly manipulating said cell to express recombinant glycosyl transferase.

Assignments (7)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.
Reel/Frame 070551/0095 →
SECURITY INTEREST Recorded Jan 19, 2024
From: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; THERAS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066355/0126 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
Reel/Frame 066167/0462 →
SECURITY INTEREST Recorded Jan 17, 2024
From: CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066342/0154 →
SECURITY INTEREST Recorded Nov 17, 2021
From: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058144/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.; LOTUS TISSUE REPAIR, INC.
To: PHOENIX TISSUE REPAIR, INC.
Reel/Frame 043447/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2014
From: VISWANATHAN, MALINI; DE SOUZA, MARK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033722/0643 →